Ofheparinsodiumforpigmucosaoflowweightheparin,averagemolecularweightof4000~6000,asanewgenerationofantithromboticdrugsresistant,hasobviousfunctionofresistingthrombosis,especiallythefirstⅩanticoagulant
Usewithnonsteroidalanti-inflammatorydrugs,aspirin,antiplateletagglutinants,dextran,andantivitaminKbecauseofthepotentialrisks.
1.Generaltreatment:120U/kgeachtime,2timesaday.2.PreventionofpostoperativeDVTformation:(1)diheparinsodium2500Uwasgiven1~2hoursbeforesurgery,andthedosewasthesameonceadayfor5~10days.(2)enoxaparinsodium30
Thrombocytopenia,abnormalliverfunctionandinjectionsitebleedingandecchymosisareseen.Occasionallyseetransaminaseandalkalinephosphatasechange.Ithasbeenreportedthatintrathecalepiduralanesthesiaandpostoper